Developer docs
API playgroundTry for free, no card

Search company profiles

ATsens

Full company profile

uuid00042ss

Namestring
ATsens
Legal namestring
주식회사 에이티센스 (ATsens Co., Ltd.)
Websiteurl
atsens.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

ATsens is a South Korean medical device company founded in September 2017 that develops wearable continuous ECG monitoring solutions for cardiology. Its flagship product, AT-Patch, is a waterproof single-lead ECG patch capable of recording up to 14 days of continuous cardiac monitoring, materially exceeding the 24–48 hour duration of conventional Holter monitors. The company serves hospitals, cardiology departments, ambulatory cardiac monitoring services, and remote patient monitoring platforms globally, with active shipments to 10 countries and distributor contracts spanning 31 countries including South Korea, the US, Japan, the UK, Germany, Greece, Brazil, Kuwait, and Poland.

The company's product architecture is centered on the AT-Heart integrated solution: AT-Patch (the 13g wearable device with IP57 waterproof rating and Bluetooth connectivity), AT-Note (a smartphone app providing real-time ECG viewing and symptom logging), and AT-Report (proprietary ECG analysis software using two-step classification algorithms to detect 17 arrhythmia types, FDA-cleared in May 2025). AT-Monitoring extends the platform to real-time in-hospital patient monitoring via Gateway-to-Cloud infrastructure with Nurses' Station alarm functionality. ATsens holds 34 healthcare patents (13 registered) including proprietary biosensor chip technology and signal processing IP. The company is broadening its sensing footprint via the AT-Heart Platform roadmap to encompass respiratory rate, body temperature, SpO2, continuous blood pressure, and continuous glucose monitoring.

ATsens generates revenue primarily through B2B sale of AT-Patch hardware via a tiered global distributor network. Pricing is quote-based with multi-year enterprise contracts; major commitments include a five-year exclusive Japan Lifeline distribution contract (~27.8B KRW, signed December 2021), a three-year US supply agreement worth approximately $370M USD covering 450,000 units (signed July 2025), and a UK NHS Supply Chain partnership enabling procurement by ~1,978 NHS facilities. Secondary revenue streams include AT-Report software, AT-Note app subscriptions, AT-Monitoring services, and Korean insurance reimbursement (EX871, approved September 2025). Revenue is projected to grow from approximately KRW 6B currently to KRW 30B+ by 2027, and the company is preparing for a KOSDAQ listing.

Short descriptiontext

ATsens is a South Korean medical device company developing the AT-Patch, a wearable continuous ECG monitor providing up to 14 days of monitoring. It serves hospitals, cardiology clinics, and ambulatory cardiac monitoring services globally through distributors spanning 31 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeongnam, South Korea
HQ citystring
Seongnam
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wearable ECG monitors, cardiac monitoring devices, arrhythmia detection systems, Holter monitoring patches, remote patient monitoring
Industry3 codes
PRIMARYHLAHACAB
Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Wearable Cardiac Monitoring Devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1AT-Patch Hardware Sales
TypeHardware Sales
Description

Sale of wearable ECG monitoring devices (AT-Patch) to healthcare providers, hospitals, and through distributor networks globally. Primary revenue driver with major three-year supply contract covering 450,000 units.

2Software and Monitoring Services
TypeSubscription Recurring
Description

Recurring revenue from AT-Note app, AT-Report analysis software, and AT-Monitoring real-time patient monitoring services, likely sold as subscriptions or per-report fees alongside hardware.

3B2B Enterprise Contracts
TypeTransaction Fee
Description

Large-scale supply agreements with institutional buyers such as the three-year $370M US distributor contract and UK NHS Supply Chain agreement, providing predictable recurring revenue.

Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels9 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Pricing details1 tier
1B2B Enterprise / Institutional Pricing
ModelUnit PricingBilling cadenceMulti-year contract
Notes

Quote-based per-unit pricing for AT-Patch devices sold to healthcare institutions and through distributor networks. Volume-based pricing implied in major supply contracts (450,000-unit three-year agreement).

GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1AT-Heart
Description

Total ECG monitoring solution consisting of AT-Patch (device), AT-Note (smartphone app), and AT-Report (analysis software) for long-term continuous ECG monitoring.

atsens.com
+4 more records
Core offering1 text field

ATsens manufactures and sells the AT-Patch, a waterproof wearable single-lead ECG monitor that records up to 14 days of continuous cardiac data, paired with the AT-Note smartphone application for real-time ECG viewing, the AT-Report AI-powered analysis software for arrhythmia detection, and the AT-Monitoring real-time in-hospital patient monitoring platform. The integrated AT-Heart solution is sold to hospitals, cardiology clinics, healthcare systems, and ambulatory cardiac monitoring service providers globally through direct enterprise sales and distributor networks.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

ATsens offers a modular platform-based product architecture centered on the AT-Heart total ECG monitoring solution. The core portfolio consists of three integrated components: AT-Patch (wearable patch-type ECG device for up to 14-day continuous monitoring), AT-Note (Bluetooth-connected smartphone app for real-time ECG viewing and symptom logging), and AT-Report (proprietary AI-powered ECG analysis software with FDA clearance). These are complemented by AT-Monitoring (real-time in-hospital patient monitoring) and the evolving AT-Heart Platform (expanding to cover total heartcare including prediction and prevention). The company is also developing additional vital sign sensing technologies including respiratory rate, body temperature, SpO2, continuous blood pressure, and continuous glucose monitoring.

Product and service5 records
1AT-Patch
CategoryWearable ECG Monitor Hardware
Description

Wearable patch-type long-term continuous ECG (Holter) monitor for detecting intermittent arrhythmias. Disposable, single-lead (Lead II) device with up to 14-day monitoring capability, IP44/IP57 waterproof rating, 13g weight, and no charging or electrode replacement required during monitoring period. Sold to hospitals, cardiology departments, and healthcare providers for arrhythmia detection, atrial fibrillation screening, and cryptogenic stroke workup.

2AT-Note
CategoryPatient Mobile Application
Description

Smartphone application providing real-time ECG viewer via Bluetooth connectivity and symptom recording functionality. Displays real-time ECG data and 3-axis motion sensor data from AT-Patch, allowing patients to log symptoms during abnormal cardiac events. Used by patients wearing the AT-Patch device under clinical supervision.

3AT-Report
CategoryECG Analysis Software
Description

ECG analysis software applying proprietary two-step classification algorithms. Enables medical institutions to analyze long-term ECG data efficiently, detect 17 types of arrhythmias, generate doctor-centric final reports with ECG strips, and export to PDF. FDA-cleared under Enhanced Level of Concern criteria for clinical use by medical professionals.

4AT-Monitoring
CategoryIn-Hospital Patient Monitoring System
Description

Real-time patient monitoring solution for hospitalized patients. AT-Patch transmits ECG signals via Bluetooth to Gateway, which sends data to Cloud for monitoring at Nurses' Station. Includes arrhythmia alarm functionality for clinical staff. Used by hospitals for inpatient cardiac monitoring.

5AT-Heart Solution
CategoryIntegrated ECG Monitoring Solution
Description

Total integrated ECG monitoring solution comprising AT-Patch (device), AT-Note (smartphone app), and AT-Report (analysis software). Enables long-term continuous ECG monitoring for up to 14 days with real-time viewing and AI-powered analysis. Marketed to hospitals and cardiology practices as a complete end-to-end cardiac monitoring platform.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

MOU signed 2025 for joint research and development of pet wearable ECG monitoring technology, extending ATsens' core wearable ECG technology into the veterinary animal health market.

2People & Technology
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

MOU signed 2025 for real-time patient monitoring collaboration, focused on integrating ATsens' ECG monitoring technology with broader patient monitoring platforms.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-01-01
Description

Domestic Korean distribution agreement signed 2022 for AT-Patch ECG monitoring device distribution within South Korea, utilizing Hanmi Pharmaceutical's established pharmaceutical and medical device distribution infrastructure.

4UK NHS Supply Chain
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-01-01
Description

Supply chain agreement established 2022 with NHS Supply Chain, the procurement and supply organization for the UK National Health Service, enabling AT-Patch ECG devices to be procured through the NHS supply chain.

5DCM DOLMED S.A. (Poland)
Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-01-01
Description

Supply MOU signed 2022 for ECG patch supply to Poland through DCM DOLMED S.A., a Polish medical device distributor.

6Kuwait DMC (AI Dabbous Medical Company)
Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-01-01
Description

Export contract signed 2022 for AT-Patch distribution in Kuwait through AI Dabbous Medical Company (Kuwait DMC), a Kuwait-based medical device distributor.

7GS Global
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-01-01
Description

Non-exclusive distribution MOU signed 2021 for North American market entry. Expanded in July 2025 with a three-year supply contract covering approximately 450,000 units (~$370M USD), with initial delivery of ~100,000 units scheduled for 2026.

8Japan Lifeline
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-01-01
Description

Distribution agreement signed 2021 for AT-Patch product distribution in Japan, leveraging Japan Lifeline's established medical device distribution network and regulatory relationships in the Japanese market.

Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-01-01
Description

Export contract signed 2021 for AT-Patch distribution in Greece through EnaMed, a Greek medical device and healthcare distributor.

10Pratixia (Brazil)
Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-01-01
Description

Export contract signed 2021 for AT-Patch distribution in Brazil through Pratixia, a Brazilian medical device distributor.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Smart hospital platform collaboration established 2021, integrating AT-Patch ECG monitoring into the hospital's smart hospital digital infrastructure for enhanced cardiac care pathways.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Clinical validation partnership for AT-Patch technology, conducting clinical studies and real-world evidence generation to support regulatory submissions and clinical adoption.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Clinical validation partnership for AT-Patch technology, supporting clinical evidence generation for arrhythmia detection and cardiac monitoring applications.

Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-01-01
Description

Domestic Korean distribution partnership established 2020 for AT-Patch distribution within South Korea.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

China-based global medical device manufacturer offering patient monitoring, ECG, and cardiology diagnostic equipment across emerging and developed markets. Competes with ATsens in the multi-vital signs monitoring category where ATsens is expanding (AT-Heart Platform roadmap).

TypeBroad incumbent
Description

Spacelabs (an OSI Systems company) manufactures patient monitoring and cardiac diagnostic equipment, including Holter analysis and ambulatory ECG systems. Overlaps with ATsens in clinical cardiac monitoring for hospital and ambulatory settings.

TypeEmerging player
Description

Biotricity develops wearable cardiac monitoring devices (Bioflux MCT, Biolife) targeting ambulatory and remote patient monitoring use cases. Smaller and earlier-stage than ATsens but addresses overlapping clinical indications with patch-based continuous monitoring.

TypeDirect peer
Description

AliveCor offers KardiaMobile ECG devices (single-lead and 6-lead) paired with AI-based arrhythmia detection algorithms and a smartphone-connected workflow. Comparable to ATsens in the AI-powered ECG analysis software and consumer/clinical hybrid positioning, though more focused on spot recording vs continuous monitoring.

TypeBroad incumbent
Description

Preventice (acquired by Boston Scientific in 2022) developed the BodyGuardian series of remote cardiac monitors, directly competitive with AT-Patch. Now operates within Boston Scientific's broader cardiac diagnostics portfolio, representing a large incumbent with similar patch/Holter technology plus broader infrastructure.

TypeBroad incumbent
Description

Philips acquired BioTelemetry in 2021, integrating MCOT (Mobile Cardiac Outpatient Telemetry) and LifeWatch into its Connected Care segment. BioTel Heart is a major US patch/cardiac monitoring service with established reimbursement, competing head-to-head with ATsens in the same clinical use cases.

7Nihon Kohden
TypeRegional player
Description

Leading Japanese medical electronics company specializing in patient monitoring, ECG, and neurology diagnostics. Operates broadly in the same clinical space as ATsens but primarily within Japan; competes with AT-Patch in Japanese hospitals via established distribution and broader installed base.

TypeRegional player
Description

Japan-based manufacturer of ECG Holter monitors, patient monitors, and cardiology diagnostic equipment with deep PMDA-cleared product portfolio. Most directly comparable to ATsens in the Japanese market where ATsens has secured Japan Lifeline partnership; a potential alternative supply partner or competitive threat.

TypeBroad incumbent
Description

Medtronic offers the SEEQ Mobile Cardiac Telemetry system and LINQ insertable cardiac monitor, representing a large incumbent in cardiac diagnostics with deeper R&D and direct sales reach. Competes with ATsens in ambulatory monitoring and arrhythmia detection across hospital and outpatient channels.

TypeDirect peer
Description

iRhythm is the most direct competitor with its Zio long-term continuous ECG patch monitor and central lab analysis service. ATsens explicitly competes against iRhythm with AT-Patch and the on-premise AT-Report model positioning as an alternative to Zio's central lab interpretation service.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights8 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ATsens

Wearable Cardiac Monitoring Devicesatsens.com

ATsens is a South Korean medical device company developing the AT-Patch, a wearable continuous ECG monitor providing up to 14 days of monitoring. It serves hospitals, cardiology clinics, and ambulatory cardiac monitoring services globally through distributors spanning 31 countries.

What ATsens does

ATsens is a South Korean medical device company founded in September 2017 that develops wearable continuous ECG monitoring solutions for cardiology. Its flagship product, AT-Patch, is a waterproof single-lead ECG patch capable of recording up to 14 days of continuous cardiac monitoring, materially exceeding the 24–48 hour duration of conventional Holter monitors. The company serves hospitals, cardiology departments, ambulatory cardiac monitoring services, and remote patient monitoring platforms globally, with active shipments to 10 countries and distributor contracts spanning 31 countries including South Korea, the US, Japan, the UK, Germany, Greece, Brazil, Kuwait, and Poland.

The company's product architecture is centered on the AT-Heart integrated solution: AT-Patch (the 13g wearable device with IP57 waterproof rating and Bluetooth connectivity), AT-Note (a smartphone app providing real-time ECG viewing and symptom logging), and AT-Report (proprietary ECG analysis software using two-step classification algorithms to detect 17 arrhythmia types, FDA-cleared in May 2025). AT-Monitoring extends the platform to real-time in-hospital patient monitoring via Gateway-to-Cloud infrastructure with Nurses' Station alarm functionality. ATsens holds 34 healthcare patents (13 registered) including proprietary biosensor chip technology and signal processing IP. The company is broadening its sensing footprint via the AT-Heart Platform roadmap to encompass respiratory rate, body temperature, SpO2, continuous blood pressure, and continuous glucose monitoring.

ATsens generates revenue primarily through B2B sale of AT-Patch hardware via a tiered global distributor network. Pricing is quote-based with multi-year enterprise contracts; major commitments include a five-year exclusive Japan Lifeline distribution contract (~27.8B KRW, signed December 2021), a three-year US supply agreement worth approximately $370M USD covering 450,000 units (signed July 2025), and a UK NHS Supply Chain partnership enabling procurement by ~1,978 NHS facilities. Secondary revenue streams include AT-Report software, AT-Note app subscriptions, AT-Monitoring services, and Korean insurance reimbursement (EX871, approved September 2025). Revenue is projected to grow from approximately KRW 6B currently to KRW 30B+ by 2027, and the company is preparing for a KOSDAQ listing.

ATsens firmographics

Firmographics
Name
ATsens
Legal name
주식회사 에이티센스 (ATsens Co., Ltd.)
Website
https://atsens.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
ATsens is a South Korean medical device company developing the AT-Patch, a wearable continuous ECG monitor providing up to 14 days of monitoring. It serves hospitals, cardiology clinics, and ambulatory cardiac monitoring services globally through distributors spanning 31 countries.
Ownership category
akta.pro rank

ATsens industry classification

Industry
Product category
Wearable Cardiac Monitoring Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHACAB
Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)

Keywords

  • Wearable ECG monitors
  • Cardiac monitoring devices
  • Arrhythmia detection systems
  • Holter monitoring patches
  • Remote patient monitoring

Where ATsens is headquartered

Location

Headquarters

HQ city
Seongnam
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

ATsens business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. AT-Patch Hardware Sales: Sale of wearable ECG monitoring devices (AT-Patch) to healthcare providers, hospitals, and through distributor networks globally. Primary revenue driver with major three-year supply contract covering 450,000 units.
  2. Software and Monitoring Services: Recurring revenue from AT-Note app, AT-Report analysis software, and AT-Monitoring real-time patient monitoring services, likely sold as subscriptions or per-report fees alongside hardware.
  3. B2B Enterprise Contracts: Large-scale supply agreements with institutional buyers such as the three-year $370M US distributor contract and UK NHS Supply Chain agreement, providing predictable recurring revenue.

Pricing tiers

ModelBillingPrice
Unit PricingMulti-year contractB2B Enterprise / Institutional Pricing

Go-to-market motion3 records

Distribution channels9 records

Marketing channels3 records

ATsens product offering

Product offering

Core offering

ATsens manufactures and sells the AT-Patch, a waterproof wearable single-lead ECG monitor that records up to 14 days of continuous cardiac data, paired with the AT-Note smartphone application for real-time ECG viewing, the AT-Report AI-powered analysis software for arrhythmia detection, and the AT-Monitoring real-time in-hospital patient monitoring platform. The integrated AT-Heart solution is sold to hospitals, cardiology clinics, healthcare systems, and ambulatory cardiac monitoring service providers globally through direct enterprise sales and distributor networks.

Product overview

ATsens offers a modular platform-based product architecture centered on the AT-Heart total ECG monitoring solution. The core portfolio consists of three integrated components: AT-Patch (wearable patch-type ECG device for up to 14-day continuous monitoring), AT-Note (Bluetooth-connected smartphone app for real-time ECG viewing and symptom logging), and AT-Report (proprietary AI-powered ECG analysis software with FDA clearance). These are complemented by AT-Monitoring (real-time in-hospital patient monitoring) and the evolving AT-Heart Platform (expanding to cover total heartcare including prediction and prevention). The company is also developing additional vital sign sensing technologies including respiratory rate, body temperature, SpO2, continuous blood pressure, and continuous glucose monitoring.

Differentiator

Problem solved

Functional benefit

Brands

  • AT-Heart: Total ECG monitoring solution consisting of AT-Patch (device), AT-Note (smartphone app), and AT-Report (analysis software) for long-term continuous ECG monitoring.
  • AT-Patch
  • AT-Note
  • AT-Report
  • AT-Monitoring

Products and services

  • AT-Patch Wearable patch-type long-term continuous ECG (Holter) monitor for detecting intermittent arrhythmias. Disposable, single-lead (Lead II) device with up to 14-day monitoring capability, IP44/IP57 waterproof rating, 13g weight, and no charging or electrode replacement required during monitoring period. Sold to hospitals, cardiology departments, and healthcare providers for arrhythmia detection, atrial fibrillation screening, and cryptogenic stroke workup.
  • AT-Note Smartphone application providing real-time ECG viewer via Bluetooth connectivity and symptom recording functionality. Displays real-time ECG data and 3-axis motion sensor data from AT-Patch, allowing patients to log symptoms during abnormal cardiac events. Used by patients wearing the AT-Patch device under clinical supervision.
  • AT-Report ECG analysis software applying proprietary two-step classification algorithms. Enables medical institutions to analyze long-term ECG data efficiently, detect 17 types of arrhythmias, generate doctor-centric final reports with ECG strips, and export to PDF. FDA-cleared under Enhanced Level of Concern criteria for clinical use by medical professionals.
  • AT-Monitoring Real-time patient monitoring solution for hospitalized patients. AT-Patch transmits ECG signals via Bluetooth to Gateway, which sends data to Cloud for monitoring at Nurses' Station. Includes arrhythmia alarm functionality for clinical staff. Used by hospitals for inpatient cardiac monitoring.
  • AT-Heart Solution Total integrated ECG monitoring solution comprising AT-Patch (device), AT-Note (smartphone app), and AT-Report (analysis software). Enables long-term continuous ECG monitoring for up to 14 days with real-time viewing and AI-powered analysis. Marketed to hospitals and cardiology practices as a complete end-to-end cardiac monitoring platform.

Companies that use ATsens

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

ATsens technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature5 records

ATsens partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered minor, core and secondary.

  • Nel Animal Medical CenterminorStrategic or Co-development Partner · 1 January 2025MOU signed 2025 for joint research and development of pet wearable ECG monitoring technology, extending ATsens' core wearable ECG technology into the veterinary animal health market.
  • People & TechnologyminorStrategic or Co-development Partner · 1 January 2025MOU signed 2025 for real-time patient monitoring collaboration, focused on integrating ATsens' ECG monitoring technology with broader patient monitoring platforms.
  • Hanmi PharmaceuticalcoreChannel Partner/ Reseller/ Distributor · 1 January 2022Domestic Korean distribution agreement signed 2022 for AT-Patch ECG monitoring device distribution within South Korea, utilizing Hanmi Pharmaceutical's established pharmaceutical and medical device distribution infrastructure.
  • UK NHS Supply ChaincoreChannel Partner/ Reseller/ Distributor · 1 January 2022Supply chain agreement established 2022 with NHS Supply Chain, the procurement and supply organization for the UK National Health Service, enabling AT-Patch ECG devices to be procured through the NHS supply chain.
  • DCM DOLMED S.A. (Poland)secondaryChannel Partner/ Reseller/ Distributor · 1 January 2022Supply MOU signed 2022 for ECG patch supply to Poland through DCM DOLMED S.A., a Polish medical device distributor.
  • Kuwait DMC (AI Dabbous Medical Company)secondaryChannel Partner/ Reseller/ Distributor · 1 January 2022Export contract signed 2022 for AT-Patch distribution in Kuwait through AI Dabbous Medical Company (Kuwait DMC), a Kuwait-based medical device distributor.
  • GS GlobalcoreChannel Partner/ Reseller/ Distributor · 1 January 2021Non-exclusive distribution MOU signed 2021 for North American market entry. Expanded in July 2025 with a three-year supply contract covering approximately 450,000 units (~$370M USD), with initial delivery of ~100,000 units scheduled for 2026.
  • Japan LifelinecoreChannel Partner/ Reseller/ Distributor · 1 January 2021Distribution agreement signed 2021 for AT-Patch product distribution in Japan, leveraging Japan Lifeline's established medical device distribution network and regulatory relationships in the Japanese market.
  • EnaMed (Greece)secondaryChannel Partner/ Reseller/ Distributor · 1 January 2021Export contract signed 2021 for AT-Patch distribution in Greece through EnaMed, a Greek medical device and healthcare distributor.
  • Pratixia (Brazil)secondaryChannel Partner/ Reseller/ Distributor · 1 January 2021Export contract signed 2021 for AT-Patch distribution in Brazil through Pratixia, a Brazilian medical device distributor.
  • Chungnam National University Sejong HospitalcoreStrategic or Co-development Partner · 1 January 2021Smart hospital platform collaboration established 2021, integrating AT-Patch ECG monitoring into the hospital's smart hospital digital infrastructure for enhanced cardiac care pathways.
  • Seoul National University Bundang HospitalcoreStrategic or Co-development Partner · 1 January 2021Clinical validation partnership for AT-Patch technology, conducting clinical studies and real-world evidence generation to support regulatory submissions and clinical adoption.
  • Kyungpook National University HospitalcoreStrategic or Co-development Partner · 1 January 2021Clinical validation partnership for AT-Patch technology, supporting clinical evidence generation for arrhythmia detection and cardiac monitoring applications.
  • iMarketkoreasecondaryChannel Partner/ Reseller/ Distributor · 1 January 2020Domestic Korean distribution partnership established 2020 for AT-Patch distribution within South Korea.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

ATsens competitors and assessment

Company assessment

Broad incumbents

  • Mindray: China-based global medical device manufacturer offering patient monitoring, ECG, and cardiology diagnostic equipment across emerging and developed markets. Competes with ATsens in the multi-vital signs monitoring category where ATsens is expanding (AT-Heart Platform roadmap).
  • Spacelabs Healthcare: Spacelabs (an OSI Systems company) manufactures patient monitoring and cardiac diagnostic equipment, including Holter analysis and ambulatory ECG systems. Overlaps with ATsens in clinical cardiac monitoring for hospital and ambulatory settings.
  • Preventice Solutions (Boston Scientific): Preventice (acquired by Boston Scientific in 2022) developed the BodyGuardian series of remote cardiac monitors, directly competitive with AT-Patch. Now operates within Boston Scientific's broader cardiac diagnostics portfolio, representing a large incumbent with similar patch/Holter technology plus broader infrastructure.
  • Philips (BioTel Heart): Philips acquired BioTelemetry in 2021, integrating MCOT (Mobile Cardiac Outpatient Telemetry) and LifeWatch into its Connected Care segment. BioTel Heart is a major US patch/cardiac monitoring service with established reimbursement, competing head-to-head with ATsens in the same clinical use cases.
  • Medtronic: Medtronic offers the SEEQ Mobile Cardiac Telemetry system and LINQ insertable cardiac monitor, representing a large incumbent in cardiac diagnostics with deeper R&D and direct sales reach. Competes with ATsens in ambulatory monitoring and arrhythmia detection across hospital and outpatient channels.

Emerging players

  • Biotricity: Biotricity develops wearable cardiac monitoring devices (Bioflux MCT, Biolife) targeting ambulatory and remote patient monitoring use cases. Smaller and earlier-stage than ATsens but addresses overlapping clinical indications with patch-based continuous monitoring.

Direct peers

  • AliveCor: AliveCor offers KardiaMobile ECG devices (single-lead and 6-lead) paired with AI-based arrhythmia detection algorithms and a smartphone-connected workflow. Comparable to ATsens in the AI-powered ECG analysis software and consumer/clinical hybrid positioning, though more focused on spot recording vs continuous monitoring.
  • iRhythm Technologies: iRhythm is the most direct competitor with its Zio long-term continuous ECG patch monitor and central lab analysis service. ATsens explicitly competes against iRhythm with AT-Patch and the on-premise AT-Report model positioning as an alternative to Zio's central lab interpretation service.

Regional players

  • Nihon Kohden: Leading Japanese medical electronics company specializing in patient monitoring, ECG, and neurology diagnostics. Operates broadly in the same clinical space as ATsens but primarily within Japan; competes with AT-Patch in Japanese hospitals via established distribution and broader installed base.
  • Fukuda Denshi: Japan-based manufacturer of ECG Holter monitors, patient monitors, and cardiology diagnostic equipment with deep PMDA-cleared product portfolio. Most directly comparable to ATsens in the Japanese market where ATsens has secured Japan Lifeline partnership; a potential alternative supply partner or competitive threat.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights8 records

Customer concentration

ATsens social profiles

Digital presence

ATsens compliance and trust

Trust signal

Compliance5 records

ATsens financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ATsens leadership team

Management profile

Number of profiles

Profiles3 records

ATsens funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ATsens M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ATsens

What does ATsens do?

ATsens manufactures and sells the AT-Patch, a waterproof wearable single-lead ECG monitor that records up to 14 days of continuous cardiac data, paired with the AT-Note smartphone application for real-time ECG viewing, the AT-Report AI-powered analysis software for arrhythmia detection, and the AT-Monitoring real-time in-hospital patient monitoring platform. The integrated AT-Heart solution is sold to hospitals, cardiology clinics, healthcare systems, and ambulatory cardiac monitoring service providers globally through direct enterprise sales and distributor networks.

Is ATsens a public or private company?

ATsens is a private company. It is classified as venture growth investor backed and is currently operating.

When was ATsens founded?

ATsens was founded in 2017. It employs 11 to 50 people.

Where is ATsens based?

ATsens is headquartered in Seongnam, South Korea, in the Asia region.

How does ATsens make money?

Three revenue lines are on record. AT-Patch Hardware Sales are the primary driver. The others are software and Monitoring Services and B2B Enterprise Contracts.

Who are ATsens's main competitors?

Broad incumbents on record are Mindray, Spacelabs Healthcare, Preventice Solutions (Boston Scientific), Philips (BioTel Heart) and Medtronic. Biotricity is listed as an emerging player. Direct peers are AliveCor and iRhythm Technologies. Regional players are Nihon Kohden and Fukuda Denshi.

Does ATsens have an API?

No public API is recorded for ATsens.

What industry is ATsens in?

ATsens's product category is Wearable Cardiac Monitoring Devices. Its primary akta.pro industry code is HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders), with a secondary code of HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals